Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment
To evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors. Efficacy is defined as the proportion of patients showing stable disease (SD), partia...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with moderate to severe atopic dermatitis
EASI50 response, defined as a decrease in Eczema Area and Severity Index (EASI) of at least 50% compared to baseline
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease
To assess the long-term safety and tolerability of AIN457 in patients with moderate to severe Crohn’s disease who participated in the core CAIN457A2202 phase II proof-of-concept study
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extension phase up to a total of 60 weeks in patients with active rheumatoid arthritis despite stable treatment with methotrexate
Efficacy of AIN457 at 16 weeks on ACR20 response.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A phase IA/II, two-arm, multi-center, open-label, dose-escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies
1. MTD and DLT of single agent LBH589B when administered orally, once-a-day on MWF, every week, in adult patients with advanced hematologic malignancies which has progressed despite standard therapy o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
Essai de phase 1b, visant à rechercher les doses de MEK162 et de BYL719 à administrer en association et à évaluer la sécurité d’emploi de cette association, chez patients ayant une tumeur solide avancée. [essai clos aux inclusions]
L’objectif de cet essai est de déterminer les doses les plus adaptées de l’association de BYL719 et de MEK162 et d’évaluer la tolérance de cette association, chez des patients ayant une tumeur solide ...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 device
To assess the bronchodilator effect of once-daily indacaterol as a PulmoSphereTM formulation and lactose-blended indacaterol in adult patients with persistent asthma compared with placebo as measured ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Service AG
Update Il y a 5 ans
Efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
To demonstrate the superiority of NVA237 50 µg + indacaterol 150 µg administered once daily as compared with indacaterol 150 µg administered once daily in terms of trough FEV1 at Week 12.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Six-month open label extension to an efficacy and safety study of Ritalin LA in the treatment of adult patients with childhood-onset ADHD
•To evaluate the long-term safety of Ritalin LA administered once daily for six months during open-label treatment in adults with ADHD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma
Update Il y a 5 ans
A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)
To demonstrate the superior bronchodilatory efficacy of QVA149 300/50 versus placebo in patients with moderate to severe stable COPD in terms of trough FEV1 (mean of evaluations at 23h 15min and 23h 4...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
21
22
23
24
25
26
27
28
29
30
Next